# Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
Canonical URL: https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5
Ticker: PRGO
Company: Perrigo Company PLC
Source: Perrigo Company PLC
Published: 2026-07-22 12:30 EST
Original Source URL: https://investor.perrigo.com/2026-07-22-Perrigo-to-Release-Second-Quarter-2026-Financial-Results-on-August-5,-2026
## Summary

Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its second quarter 2026 financial results on Wednesday, August 5th,...

## Article Body
, / PRNewswire / -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its second quarter 2026 financial results on Wednesday, August 5 th , 2026. The company will hold a conference call beginning at 8:30 a.m. (EST) hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra.

The earnings conference call will be available live via webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, U.S., 646-357-8785, International, and conference ID 98476. A replay of the call will be available beginning at approximately 12:00 p.m. (EST) Wednesday, August 5, through Wednesday, August 12, 2026. To access the replay, dial 888-660-6345, U.S., 646-517-4150, International, and enter access code 98476 #.

About Perrigo

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill ® , Mederma ® , Compeed ® , EllaOne ® , and Jungle Formula ® .

For more information, visit www.perrigo.com .

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings , for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.

Perrigo Contacts

Eric Jacobson, Vice President, Global Investor Relations (616) 886-0375, eric.jacobson@perrigo.com

Nick Gallagher, Associate Director, Global Investor Relations (269) 686-3238, nicholas.gallagher@perrigo.com

SOURCE Perrigo Company plc
## Recent Company News
- 2026-07-22 12:30 EST — [Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5) — Source: Perrigo Company PLC
- 2026-06-30 20:25 EST — [Perrigo Announces Appointment of Two New Independent Directors to Board](https://biopharmsignal.com/news/PRGO/perrigo-announces-appointment-of-two-new-independent-directors-to-board-47cee7b5) — Source: Perrigo Company PLC
- 2026-06-08 20:31 EST — [Perrigo Announces Leadership Transition](https://biopharmsignal.com/news/PRGO/perrigo-announces-leadership-transition-fef2604a) — Source: Perrigo Company PLC
- 2026-05-26 12:30 EST — [Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-oppenheimer-26th-annual-consumer-growth-and-e-commerce-conference) — Source: Perrigo Company PLC
- 2026-05-06 10:30 EST — [Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations](https://biopharmsignal.com/news/PRGO/perrigo-reports-first-quarter-2026-financial-results-from-continuing-operations) — Source: PRGO
## Related News
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)
- 2026-07-22 12:08 EST — BIAF — [bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-and-pictor-inc-partner-to-develop-and-commercialize-bio-7ee819d4)
- 2026-07-22 12:00 EST — MNPR — [Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-initiates-rolling-nda-submission-for-alxn1840-in-wilson-disease-e671ddcf)
- 2026-07-22 11:00 EST — CRIS — [Curis Announces Positive Emavusertib Update](https://biopharmsignal.com/news/CRIS/curis-announces-positive-emavusertib-update-0e0fa8ea)